The Hetero Ring Contains At Least Three Nitrogens Patents (Class 540/474)
-
Publication number: 20090169479Abstract: The present invention relates to a compound of formula (II) chosen from (IIa) and (IIb) or of formula (VI) chosen from (VIa) and (VIb) of following general formulae: in which: X1, X2, X3, X4 and X5 represent, independently of one another, L-Y in which L represents a C1-C3 alkyl group, preferably (CH2), with n=1 to 3, Y represents —CONH2, —CO—NR7R8 or —NR7-CO—R8, or an isomer, an enantiomer or a diastereoisomer of these or their mixtures or a pharmaceutically acceptable salt of the compounds of formulae (VIa) and (VIb). It also relates to a complex of these compounds with a paramagnetic metal or a radionuclide and their use in diagnostic methods.Type: ApplicationFiled: October 9, 2006Publication date: July 2, 2009Applicant: GUERBETInventor: Marc Port
-
Publication number: 20090156801Abstract: This invention concerns novel labeling reactants based on azacycloalkanes, wherein a suitable group is linked to the molecule allowing introduction of the said molecules to bioactive molecules in solution or on solid phase.Type: ApplicationFiled: May 4, 2007Publication date: June 18, 2009Applicant: NXP B.V.Inventor: Jari Hovinen
-
Publication number: 20090053137Abstract: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and a metal coordinating moiety comprising a substituted phenyl, pyridyl, or pyrimidyl derivative.Type: ApplicationFiled: March 14, 2007Publication date: February 26, 2009Inventor: Dennis A. Moore
-
Publication number: 20090048222Abstract: The invention provides certain macrocyclic triaza compounds which down-regulate CD4 expression for use in the treatment of autoimmune diseases and inflammatory diseases or conditions. In a specific embodiment, the invention provides certain naphthalene substituted triaza macrocycles which exhibit high activity for down regulation of CD4 expression. In particular, triaza macrocycles having dansyl groups are provided for use in pharmaceutical compositions.Type: ApplicationFiled: October 12, 2007Publication date: February 19, 2009Inventors: Thomas Bell, Dominique Schols, Kaka Dey, Kurt Vermeire
-
Patent number: 7488820Abstract: The present invention is directed, in part, to naphthofluorescein-based ligands for detection of metal ions, and methods of making and using the same.Type: GrantFiled: January 19, 2005Date of Patent: February 10, 2009Assignee: Massachusetts Institute of TechnologyInventors: Stephen J. Lippard, Christopher J. Chang, Elizabeth M. Nolan
-
Publication number: 20090036674Abstract: Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.Type: ApplicationFiled: March 14, 2007Publication date: February 5, 2009Inventor: Dennis A. Moore
-
Publication number: 20090010845Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.Type: ApplicationFiled: September 10, 2008Publication date: January 8, 2009Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
-
Patent number: 7470469Abstract: A medical device comprising a substrate having a plasma polymerized functionality bonded to at least a portion of the substrate. A superoxide dismutase mimic agent having a complimentary functional group to the plasma polymerized functionality is bonded to the portion of the substrate by bonding to the plasma polymerized functionality. The functionalities can be carboxylate, amine, or sulfate groups and/or polyethylene glycol and can optionally include crosslinking groups.Type: GrantFiled: July 5, 2007Date of Patent: December 30, 2008Assignee: Advanced Cardiovascular Systems Inc.Inventors: Eugene T. Michal, Murthy Simhambhatla, Charles D. Claude
-
Publication number: 20080312431Abstract: The invention provides a compound comprising a xanthone or thiaxanthone sensitising moiety, capable of coordinating to a lanthanide ion by the nitrogen atom of an integral pyridyl group or a related group able to bind a lanthanide ion.Type: ApplicationFiled: May 11, 2006Publication date: December 18, 2008Inventors: David Parker, Robert Pal, Junhua Yu
-
Publication number: 20080312430Abstract: The present invention relates to novel processes for the synthesis of polyazamacrocycle derivatives. Furthermore, the present invention relates to novel polyazamacrocycle derivatives as well as novel intermediates for the synthesis of said polyazamacrocycle derivatives.Type: ApplicationFiled: October 20, 2005Publication date: December 18, 2008Applicant: THERAPHARM GMBHInventors: Simon Cihelnik, Ladislav Droz, Martin Sramek
-
Publication number: 20080267866Abstract: A compound of Formulae (1), (2) or (3), A1-Ph (1) or A1-Ar-A2 (2) or A1-(A2)A?-A3 (3) wherein A1, A2 and A3 are selected from Formulae (4), (5) and (6), or a salt whereof; wherein Ar is selected from the group consisting of 1,2-phenyl, 1,3-phenyl and 1,4-phenyl optionally substituted with one or more methyl groups; m and n are independently integers from 0 to 1; Ph is phenyl, optionally substituted with one or more methyl groups; Ar1 is trisubstituted phenyl optionally substituted with one or more phenyl groups; and R1, R2 and R3 are independently selected from the group consisting of H, Me and linear chain C2-C4 alkyl.Type: ApplicationFiled: June 10, 2005Publication date: October 30, 2008Applicant: UNIVERSITY OF HULLInventors: Stephen James Archibald, Elizabeth Amie Lewis, Timothy J. Hubin
-
Patent number: 7432371Abstract: Nanofilms useful for filtration are prepared from oriented amphiphilic molecules and oriented macrocyclic modules. The amphiphilic species may be oriented on an interface or surface. The nanofilm may be prepared by depositing or attaching an oriented layer to a substrate. A nanofilm may also be prepared by coupling the oriented macrocyclic modules to provide a membrane.Type: GrantFiled: February 7, 2003Date of Patent: October 7, 2008Assignee: Covalent Partners, LLCInventors: Joshua W. Kriesel, Timothy B. Karpishin, Donald B. Bivin, Grant Merrill, Martin S. Edelstein, Thomas H. Smith, Jeffery A. Whiteford, Robert T. Jonas, Mark Micklatcher, Serena Joshi
-
Publication number: 20080241873Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.Type: ApplicationFiled: March 4, 2008Publication date: October 2, 2008Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
-
Patent number: 7414065Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: November 17, 2004Date of Patent: August 19, 2008Assignee: Genzyme CorporationInventors: Gary J. Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
-
Publication number: 20080188422Abstract: Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.Type: ApplicationFiled: June 1, 2005Publication date: August 7, 2008Applicant: The Ohio State University Research Office of Technology Licensing & CommercializationInventors: James A. Cowan, Yan Jin, Seth Bradford, Nikhil Gokhale, Ada Cowan, Chun-An Chen
-
Publication number: 20080181847Abstract: The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (i.e. biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.Type: ApplicationFiled: October 4, 2005Publication date: July 31, 2008Applicant: KONINKLIJKE PHILIPS ELECTRONICS, N.V.Inventors: Marc Stefan Robillard, Holger Gruell
-
Publication number: 20080167443Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.Type: ApplicationFiled: December 17, 2007Publication date: July 10, 2008Applicant: WALLAC OYInventors: Jari Hovinen, Veli-Matti Mukkala, Harri Hakala, Jari Peuralahti
-
Publication number: 20080167334Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.Type: ApplicationFiled: August 2, 2006Publication date: July 10, 2008Inventors: Eric R. Prossnitz, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young
-
Publication number: 20080159954Abstract: The invention relates to the subjects characterized in the patent claims, namely metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use, processes for their preparation and their use in NMR and X-ray diagnosis, radiodiagnosis and radiotherapy, and in MRT lymphography.Type: ApplicationFiled: October 17, 2007Publication date: July 3, 2008Inventors: Johannes Platzek, Heiko Schirmer, Hanns-Joachim Weinmann, Bernd Misselwitz, Ludwig Zorn
-
Patent number: 7390828Abstract: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumoursType: GrantFiled: February 15, 2002Date of Patent: June 24, 2008Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Giovanni Paganelli, Marco Chinol, Mauro Ginanneschi
-
Publication number: 20080145311Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.Type: ApplicationFiled: October 9, 2007Publication date: June 19, 2008Inventors: Gregory M. LANZA, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
-
Patent number: 7385054Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine, and A1 and A2 have different meanings, are suitable as contrast media.Type: GrantFiled: November 14, 2005Date of Patent: June 10, 2008Assignee: Schering AGInventors: Johannes Platzek, Heiko Schirmer, Hanns-Joachim Weinmann, Jose Luis Martin, Juan R. Harto
-
Publication number: 20080124270Abstract: New compounds are provided that may be used to chelute a metal. The compound comprise polyazamacrocyclic compound with at least one phosphonic group substituted on at least one of the aza groups of the polyazamacrocyclic compound. Methods for preparing the compounds are also provided. Methods for preparing a diagnostic imaging agent using the compounds and methods for diagnostic imaging are further provided. Methods for preparing a therapeutic agent using the compounds and methods for therapy are further provided.Type: ApplicationFiled: December 20, 2004Publication date: May 29, 2008Applicant: BRACCO IMAGING S.P.A.Inventors: Michael F. Tweedle, Hong Fan, Luciano Lattuada, Kondareddiar Ramalingam, Rolf E. Swenson
-
Publication number: 20080107606Abstract: The present invention relates to a method for preparing a bifunctional chelator for lanthanide. The method comprises the steps of providing a starting material which has an amino and carboxyl group; protecting the amino with an amino protecting group and the carboxyl with a carboxyl protecting group to produce a protected compound; reacting the protected compound with cyclen to generate a monoalkylated cyclen; reacting the monoalkylated cyclone with an activated compound to generated tetra-alkylated cyclone; removing the amino protecting group with a first protecting group removal reagent; and removing the carboxyl protecting groups with a second protecting group removal reagent to yield a bifunctional chelator having three more carboxyl groups and one or more amino groups.Type: ApplicationFiled: May 2, 2007Publication date: May 8, 2008Inventors: Douglas GROTJAHN, Eric Weiner
-
Patent number: 7368100Abstract: Backbone-substituted 1,4,7,10-tetraaza cyclododecane-N,N?,N?,N??-tetraacetic acid compounds, metal complexes thereof, compositions thereof, conjugates thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: September 5, 2003Date of Patent: May 6, 2008Assignee: The United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Publication number: 20080102026Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.Type: ApplicationFiled: October 27, 2006Publication date: May 1, 2008Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
-
Patent number: 7351389Abstract: Novel metal-chelate complexes comprising aminocarboxylate ligands including substituted aromatic amide moieties, such as those having the formula wherein R13, A1, R1 and R2 are as defined herein, are disclosed.Type: GrantFiled: October 13, 2004Date of Patent: April 1, 2008Assignee: Bracco International B.V.Inventors: Radhakrishna K. Pillai, Sang I. Kang, Edmund R. Marinelli, Ramachandran S. Ranganathan, Michael F. Tweedle
-
Patent number: 7335629Abstract: The present invention relates to support-fixed bleaching catalyst(s)suitable or the catalysis of peroxide compounds, characterized in that the support-fixed bleaching catalyst(s) is/are covalently bonded to a support by means of at least one organic ligand of the bleaching catalyst. The bleaching catalyst(s) form(s) a complex with at least on transition metal. The invention further relates to support-fixed bleaching catalysts for the catalysis of peroxide compounds, where at least one ligand, covalently bonded to a support, is a transition-metal-free ligand, which chelates with transition metal, derived from another source, preferably from the bleaching composition and/or added water and thus forms the complex with a transition metal.Type: GrantFiled: June 21, 2004Date of Patent: February 26, 2008Assignee: Henkel Kommanditgesellschaft Auf AktienInventors: Pavel Gentschev, Steve Döring, Jacques Breyer, Antonio Machin
-
Patent number: 7312327Abstract: The invention relates to a method of preparing nitrogen macrocycles having formula (I). The inventive method comprises a step involving the reaction of compounds (II) and (III) in order to form a compound having formula (IV). Said compound is subsequently made to react with a compound having formula (V) in order to form a compound having formula (VI).Type: GrantFiled: September 27, 2002Date of Patent: December 25, 2007Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Commissariat a l'energie AtomiqueInventors: Frederic Boschetti, Franck Denat, Roger Guilard, Henry Ledon, Herve Chollet, Jean-Louis Babouhot
-
Patent number: 7311970Abstract: A medical device comprising a substrate having a plasma polymerized functionality bonded to at least a portion of the substrate. A superoxide dismutase mimic agent having a complimentary functional group to the plasma polymerized functionality is bonded to the portion of the substrate by bonding to the plasma polymerized functionality.Type: GrantFiled: September 17, 2004Date of Patent: December 25, 2007Assignee: Abbott Cardiovascular Systems Inc.Inventors: Eugene T. Michal, Murthy Simhambhatla, Charles D. Claude
-
Patent number: 7267994Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules. More particularly, the invention provides Element Coded Affinity Tags comprising a metal chelate and a metal ion and methods of using the tags to detect, analyze, and identify biomolecules including polypeptides, nucleic acids, lipids, and polysaccharides.Type: GrantFiled: May 24, 2004Date of Patent: September 11, 2007Assignee: Regents of the University of CaliforniaInventors: Claude F. Meares, Carlito B. Lebrilla, Nathaniel G. Butlin, Sarah M. Cheal, Todd M. Corneillie, Susan Lee, Paul A. Whetstone, Nicolas L. Young
-
Patent number: 7214545Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules. More particularly, the invention provides Element Coded Affinity Tags comprising a metal chelate and a metal ion and methods of using the tags to detect, analyze, and identify biomolecules including polypeptides, nucleic acids, lipids, and polysaccharides.Type: GrantFiled: April 28, 2004Date of Patent: May 8, 2007Assignee: The Regents of the University of CaliforniaInventors: Claude F. Meares, Paul A. Whetstone, Todd M. Corneillie, Nathaniel G. Butlin
-
Patent number: 7211241Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.Type: GrantFiled: October 17, 2003Date of Patent: May 1, 2007Assignee: Schering AktiengesellschaftInventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
-
Patent number: 7208140Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine and A1 and A2 have different meanings, are suitable as contrast media.Type: GrantFiled: February 19, 2004Date of Patent: April 24, 2007Assignee: Schering AktiengesellschaftInventors: Heiko Schirmer, Hanns-Joachim Weinmann, Johannes Platzek, Jose Luis Martin, Juan R. Harto, Bjoern Riefke
-
Patent number: 7164016Abstract: The invention relates to macrocyclic metal complexes and their production and use for the production of conjugates with biomolecules. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of the relaxivity is made possible.Type: GrantFiled: July 19, 2002Date of Patent: January 16, 2007Assignee: Schering AGInventors: Johannes Platzek, Heribert Schmitt-Willich, Günther Michl, Thomas Frenzel, Detlev Sülzle, Hans Bauer, Bernd Radüchel, Hanns-Joachim Weinmann, Heiko Schirmer
-
Patent number: 7160872Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: June 21, 2004Date of Patent: January 9, 2007Assignee: AnorMED Inc.Inventors: Gary Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Skerlj, David Bogucki
-
Patent number: 7132513Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10.Type: GrantFiled: March 9, 2001Date of Patent: November 7, 2006Assignees: European Community, INSERM Insitut National de la Santé et de la Recherche MédicaleInventors: Ali Ouadi, Jean-François Gestin, Christos Apostolidis
-
Patent number: 7081472Abstract: Metal-complexable substituted bis-indole derivatives comprising the structure shown in formula (I) hereunder: enantiomers and pharmaceutically acceptable salts thereof and metal complexes thereof, wherein L, R1, R2, R3, C1, C2, m, n, p, q and r are as defined in claim 1 for use as constrats agents.Type: GrantFiled: November 7, 2001Date of Patent: July 25, 2006Assignee: K. U. Leuven Research & DevelopmentInventors: Erwin Cresens, Yicheng Ni, Paul Adriaens, Alfons Verbruggen, Guy Marchal
-
Patent number: 7078013Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: GrantFiled: February 10, 2004Date of Patent: July 18, 2006Assignee: Aletheon Pharmaceuticals, Inc.Inventors: Donald B Axworthy, Louis J Theodore, Linda M Gustavson, John M Reno
-
Patent number: 7060818Abstract: An improved method of synthesizing a macrocyclic tetraamido compound includes protecting the amino portion of an amino carboxylic acid to form a protected amino carboxylic acid; exposing the protected amino carboxylic acid to a first solvent, preferably a hydrocarbon solvent, such as toluene or 1,2-dichloroethane, dichloromethane, dibromomethane and 1,2-dibromoethane. The carboxylic acid portion of the protected amino carboxylic acid is then converted to an activated carboxylic acid by one of esterification or acid halide formation, to form a protected amino activated carboxylic acid derivative. The protected amino activated carboxylic acid derivative is reacted with a diamine in the presence of a second solvent, such as THF or ,2-dichloroethane, dichloromethane, dibromomethane and 1,2-dibromoethane, to form a protected diamide diamine intermediate.Type: GrantFiled: February 21, 2003Date of Patent: June 13, 2006Assignee: Carnegie Mellon UniversityInventors: Colin P. Horwitz, Anindya Ghosh
-
Patent number: 7045606Abstract: The invention concerns a ligand comprising (I) wherein n is an integer from 1 to 5 Y is CO2H or PO3H2T represents —X or -phenyl-X, wherein X represents NO2, NH2, NCS, NHCOCH2-Z, NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or NHCO(CH2)m-Q where Q is a hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, W is —(CH2)m- m is an integer from 1 to 10 Z is chloride, bromide or iodineType: GrantFiled: September 13, 2002Date of Patent: May 16, 2006Assignee: European CommunityInventors: Ali Ouadi, Jean-Francois Gestin, Christos Apostolidis
-
Patent number: 7022843Abstract: Improved ?,??-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compounds are provided as photosensitizers. Pharmaceutical compositions and photodynamic therapy comprising them are also disclosed.Type: GrantFiled: April 14, 2000Date of Patent: April 4, 2006Assignee: The University of British ColumbiaInventors: Jill Kirsten MacAlpine, Christian Brückner, David Dolphin
-
Patent number: 7022717Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: November 7, 2003Date of Patent: April 4, 2006Assignee: AnorMED, Inc.Inventors: Gary James Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
-
Patent number: 7012140Abstract: The present invention is directed, in general, to a contrast agent comprising a tetraazacyclododecane ligand and comprising a macrocyclic ring and a paramagnetic metal ion coordinated to the tetraazacyclododecane ligand. Pendent arms R, R?, R? and R?? attached to a ring nitrogen. The pendent arms have the general formula: ?C?HR1R2 and for three or more of the pendant arms a chirality of the carbon atoms C? are identical for each of three or more of the pendant arms. The R1 group is larger than hydrogen and R2 is selected from the group consisting of: an alcohol, amides, a carboxylate, phosphinates and a phosphonate. One or more substituents R6 is a group larger than a methyl group and is located on one or more ring carbons.Type: GrantFiled: July 14, 2003Date of Patent: March 14, 2006Assignees: Board of Regents, The University of Texas System, MacrocyclicsInventors: A. Dean Sherry, Mark Woods, Zoltan Kovacs
-
Patent number: 6987102Abstract: Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.Type: GrantFiled: July 30, 2002Date of Patent: January 17, 2006Assignee: Anormed, Inc.Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
-
Patent number: 6962690Abstract: Fluorescent chelates of lanthanide, terbium, europium and dysprosium with tetraazamacrocyclic compounds are discussed which can be used as fluorescent in vitro or in vivo diagnostic agents. These chelates are tissue specific imaging agents for soft tissue cancers.Type: GrantFiled: October 22, 2002Date of Patent: November 8, 2005Assignees: Dow Global Technologies Inc., Texas Tech UniversityInventors: Garry E. Kiefer, Darryl J. Bornhop
-
Patent number: 6942966Abstract: Novel macrocyclic compounds are constructed to include large cyclic structures that are interrupted by at least one ring system. Each interrupting ring system includes two bridgehead atoms. Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical functional groups. The ring systems can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring. These can also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the macrocyclic compounds. In accordance with certain embodiments of the invention, libraries of such macrocyclic compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the library.Type: GrantFiled: September 6, 1996Date of Patent: September 13, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventor: Phillip Dan Cook
-
Patent number: 6936189Abstract: A cyclic tertiary amine compound represented by a formula (1) and an organic luminescent device are disclosed. Use of the cyclic tertiary amine compound as a hole transport material, a hole injection material or an organic electroluminescent material can provide organic EL devices having high luminous efficiency and a long service life.Type: GrantFiled: March 4, 2004Date of Patent: August 30, 2005Assignee: Chisso CorporationInventors: Wang Guofang, Manabu Uchida, Hajime Yokoi, Takaharu Nakano, Kenji Furukawa
-
Patent number: 6902891Abstract: A process of fragmenting and labeling a synthetic or natural nucleic acid, comprising the steps of providing a mixture containing a nucleic acid, a labeling agent containing a detectable label, and at least one multivalent metal cation in a substantially aqueous solution; chemically fragmenting the nucleic acid in the mixture to produce a multiplicity of nucleic acid fragments; and attaching at least one label to at least one of the nucleic acid fragments to produce a detectably labeled nucleic acid fragment.Type: GrantFiled: December 15, 2000Date of Patent: June 7, 2005Assignees: Bio Merieux, Gen-Probe IncorporatedInventors: Ali Laayoun, Lionel Menou, Christelle Tora, Aloke R. Banerjee, Michael M. Becker, Kenneth A. Browne, Matthew C. Friedenberg, Fred F. Hajjar
-
Patent number: 6897209Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: August 22, 2003Date of Patent: May 24, 2005Assignee: GE Healthcare LimitedInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert